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 In the 23 years since the  rst locus for 
autosomal dominant polycystic kidney 
disease (ADPKD) was identi ed, we have 
moved from a nihilistic view that little 
could be done to alter the clinical course 
of the disease to one of enormous opti-
mism that pharmacological intervention 
may signi cantly delay the onset of end-
stage renal disease (ESRD). 1 Of course the 
latter awaits the results of several ongoing 
clinical trials, but the fact that these clini-
cal trials can now be carried out, using 
change in renal volume as a surrogate 
marker of disease progression, is in itself 
an enormous advance. * is advance also 
parallels our increasing understanding of 
the molecular pathogenesis of ADPKD. 
ADPKD is genetically heterogeneous, 
with mutations in  PKD1 and  PKD2 
accounting for 85 and 15 % of cases, 
respectively. 2 Their protein products, 
polycystin-1 and polycystin-2, form a 
mechanosensitive calcium channel and 
signaling complex that regulates the 
function of the renal primary cilium, an 
organelle that appears to be essential for 
normal tissue morphogenesis. 3 * is iden-
ti es ADPKD as the prototypic member 
of a new group of disorders called the 
ciliopathies. With over 50,000 individuals 
in the United Kingdom and 300,000 in the 
United States who have or are at risk of 
developing ADPKD, the number of indi-
viduals who are likely to bene t from cur-
rent research is considerable. 
 Much of the progress made in under-
standing the molecular pathogenesis of 
ADPKD has been dependent on careful 
clinical and pathological studies that have 
de ned the spectrum of abnormalities 
that underlie and result from the progres-
sive bilateral and o4 en massive enlarge-
ment of the kidneys that is characteristic 
and diagnostic of this condition. * is has 
also highlighted the marked clinical vari-
ability in age at ESRD and renal volume 
seen within and between families and 
individuals. This can occasionally be 
extreme, with ESRD in infancy and old 
age being observed in the same family. 
Variability of disease expression in men-
delian diseases is common, even in dis-
eases in which a single common mutation 
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 Rossetti  et al. identify non- and incompletely penetrant alleles of  PKD1 . 
Although such alleles are well recognized in other human mendelian 
disorders, they have not been associated with autosomal dominant 
polycystic kidney disease (ADPKD). These alleles produce atypical, mild, 
or severe disease depending on whether they are inherited in the 
heterozygous or homozygous state or  in trans with another mutation, 
providing an intriguing potential mechanism for the considerable  
phenotypic variability seen in families with ADPKD. 
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is found, for example,   F508 in cystic 
 brosis. Environmental factors may play 
a role but are poorly characterized in 
ADPKD. Hormonal in9 uences may be 
important, as ADPKD is typically more 
severe in men and severe polycystic liver 
disease usually a: ects women. * is sug-
gests that genetic in9 uences on disease 
severity, either genic or allelic, are more 
likely to be important. 4 
 As a consequence of the establishment 
of molecular testing for ADPKD and the 
detailed phenotyping of patients using 
renal volume measurement, there is now 
a wealth of data describing the in9 uence 
of locus and allelic heterogeneity on dis-
ease expression. In ADPKD, locus hetero-
geneity has a major effect on severity. 
Individuals with mutations in  PKD2 reach 
ESRD some 20 years later than those with 
a mutation in  PKD1 — 73 versus 54 
years  — thus explaining some of the inter-
familial variability. 5 * is e: ect is due to 
cyst number and not the rate of cyst 
growth, as more cysts develop earlier in 
 PKD1 kidneys. 6 Other genic e: ects include 
loss of  TSC2 in the  PKD1 – TSC2 conti-
guous gene deletion syndrome and bilineal 
disease due to co-inheritance of  PKD1 and 
 PKD2 mutations. 7 Several studies have 
identi ed a signi cant in9 uence of other 
genetic modi ers that may account for up 
to 78 % of the variability in ESRD. 8 
 However, it is the striking allelic hetero-
geneity in ADPKD that is providing 
insights into the molecular events under-
lying cyst formation. 2,9 The ADPKD 
mutation database describes 314 likely 
pathogenic mutations, most of which are 
private (Table 1). Nearly 300 apparently 
neutral polymorphisms and over 200 
variants of indeterminate e: ect have also 
been documented, although pathogenicity 
has been assigned to a proportion of the 
latter based on a comprehensive analysis 
using chemico-physical, structural, con-
servation, contextual, and segregation 
analysis. 2 What is also striking is the very 
large number of  PKD1 sequence variants 
detected in each individual with ADPKD, 
with a mean of 10 – 13 (range 0 – 60), with 
some patients having more than one path-
ogenic or multiple missense variants. 2,9 
However, there is little correlation between 
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Bergmann  et al. , severe  in utero disease 
was associated with a  PKD2 mutation. 15 
Pathogenic  PKD1 sequence variants were 
not reported, although no comment was 
made about the presence of  PKD1 variants 
of uncertain pathogenicity. 
 * us the number and type of sequence 
variants in  PKD1 , in combination with 
modi er genes and somatic events, may 
be a determinant of disease variability in 
ADPKD. Functional studies will clearly 
have a role in assessing the e: ects of dif-
ferent mutations but are unlikely to have 
widespread applicability to clinical molec-
ular testing in the near future. Further 
family studies, which allow segregation 
analysis and accurate renal phenotyping, 
are likely to permit better assessment of 
the role of di: erent  PKD1 sequence vari-
ants in disease expression and severity. 
 A major implication of the study of Ros-
setti  et al. 13 and other recent reports of 
comprehensive mutation analysis of  PKD1 
and  PKD2 is that pathogenic mutations 
can now be defined in about 90 % of 
probands. * e challenge is to try to use 
these data to provide better predictions of 
disease severity and prognosis to individu-
als and families coping with the lifetime 
burden of complications of ADPKD. 
 Although gene-based diagnostic testing 
in ADPKD is not indicated for the majority 
of individuals who are at risk of inheriting 
ADPKD, as imaging is a reliable diagnostic 
tool in adults, molecular analysis to deter-
mine linkage to  PKD1 or  PKD2 will have 
prognostic value. Individuals with a  PKD2 
mutation have a low risk of progressing to 
ESRD, although they require monitoring 
for hypertension and other cardiovascular 
risk factors. Mutation analysis, which now 
has a detection rate of about 90 % , may 
therefore be of value in families in whom 
linkage analysis cannot be carried out. 
Although the indications for gene-based 
molecular testing need to be rigorously 
assessed, it is clear that the families with  in 
utero and early-onset disease should be 
o: ered testing in combination with genetic 
counseling. * e recognition of hypomor-
phic  PKD1 alleles in this clinical situation 
will have important implications for genetic 
counseling and provision of prenatal 
screening and diagnosis. 
 Rossetti  et al. 13 therefore provide the 
 rst evidence that incompletely penetrant 
age at ESRD and allelic heterogeneity, in 
contrast to that observed between age at 
ESRD and locus heterogeneity. 10 * e posi-
tion, but not the type, of mutation in 
 PKD1 has a very modest effect. ESRD 
occurs at age 53 years versus 56 years 
when 5  mutations are compared with 3  
mutations. 10 For  PKD2 mutations there is 
also no clear correlation between muta-
tion type, position, and renal function. 11 
 * e lack of a clear genotype – phenotype 
correlation suggests that most mutant 
 PKD alleles, including missense changes, 
are inactivating. In addition, the rate of 
cyst formation may be dependent on other 
stochastic factors independent of the 
inherited germline  PKD1 mutation. One 
factor may be the rate of somatic mutation 
or genomic loss of the wild-type  PKD 
allele. * e focal and sporadic nature of 
cysts in human ADPKD, the detection of 
loss of heterozygosity and somatic muta-
tions in  PKD1 and  PKD2 , and orthologous 
mouse models all suggest that loss of both 
 PKD alleles is an important mechanism 
underlying renal cyst initiation. The 
greater severity of  PKD1 -associated dis-
ease could also then be explained by the 
greater complexity, GC richness, and rela-
tive instability of the  PKD1 locus predis-
posing to a higher rate of somatic mutation 
and loss of heterozygosity. 6 However, 
mouse studies have also identi ed hypo-
morphic alleles of  Pkd1 , suggesting that a 
reduction in expression may also be 
important in disease pathogenesis. 12 
 A report in  Kidney International now 
provides strong evidence for the role 
of such alleles in human ADPKD with 
non-penetrant or weakly penetrant  PKD1 
alleles significantly modifying disease 
phenotype and severity. Rossetti  et al . 13 
(this issue) describe missense  PKD1 
alleles that produce atypical, mild, or 
severe disease depending on whether they 
are inherited in the heterozygous or 
homozygous state or  in trans with a path-
ogenic truncating mutation. Intriguingly, 
all these hypomorphic alleles are predicted 
to be probably pathogenic. 
 * e identi cation of three rare families, 
two consanguineous and one with appar-
ent autosomal recessive inheritance and 
atypical ADPKD, provides the  rst evi-
dence for non-penetrant or weakly pen-
etrant  PKD1 alleles. However, it is the role 
of such alleles in modifying disease 
expression that is of great interest. 
 In a further three families with disease 
presenting  in utero , missense variants were 
found  in trans with  PKD1 -null alleles only 
in severely a: ected cases. In each case the 
missense variants, which were all arginine-
to-cysteine substitutions and presumably 
arose by spontaneous mutations at CpG 
dinucleotides, were transmitted from the 
una: ected parent. * is observation pro-
vides a molecular explanation for the recur-
rence of  in utero disease within families 
being compatible with codominant inherit-
ance of a major genetic modi er from the 
una: ected parent. 14 * e surprise is that the 
modifying gene is an allele of  PKD1 . 
 Although important and of great value 
in providing genetic counseling to fami-
lies, this pattern of inheritance is unlikely 
to account for all cases of severe early-
onset disease. In the case reported by 
 Table 1  Distribution of  PKD1 sequence variants by type and pathogenicity 
  Pathogenic  Indeterminate  Polymorphism 
 All  314 (91)  221 (16)  283 (15) 
 Nonsense  103   0    0 
 Deletion  39   2    0 
 Frameshift  127    0    0 
 Splice  37   1    0 
 Substitution    2  218  26 
 IVS silent   0   0  96 
 Synonymous   0    0  154 
 3  UTR silent   0   0   6 
 IVS, intervening sequence; UTR, untranslated region . 
 Data derived from Autosomal Dominant Polycystic Kidney Disease: Mutation Database ( http://pkdb.mayo.edu/ ), 
December 2008. Figures in parentheses represent  PKD2 mutations. 
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 PKD1 alleles exist and may account for the 
considerable variability in disease seen in 
some families. Further analysis of and addi-
tional large-scale mutation screens in 
ADPKD supported by detailed phenotypic 
analysis and family studies are now required 
to determine whether the total burden of all 
sequence variants and missense changes, 
either  in cis or  trans , is correlated with 
disease severity. It is an intriguing thought 
that total sequence variation in  PKD1 itself 
may be a major determinant of disease 
severity and variability. 
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 The goddess of the waters 
 Harry  van Goor 1 and  Henri G.D.  Leuvenink 2 
 The renal lymphatic system is cardinal in circulatory physiology and 
immunology. Sakamoto  et al. report that lymphatic angiogenesis is 
increased in tubulointerstitial lesions in human chronic renal disease 
and correlates with tissue damage. Moreover, lymphatic growth was 
associated with vascular endothelial growth factor-C (VEGF-C) expression 
in mononuclear and tubular epithelial cells. Diabetic nephropathy had 
the highest level of VEGF-C and the most extensive lymphangiogenesis. 
The data suggest that lymphangiogenesis is a common feature in the 
progression of tubulointerstitial fibrosis. 
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 Why not start with a reference to Hippoc-
rates, who is thought to have  rst discov-
ered the existence of lymph?  Lympha 
originates from the Greek word  nymphe , 
a goddess of the waters. So, it is crystal 
clear that lymph is a colorless fluid —
 except for the lymph found in the lacteal 
vessels of the mesentericum, which turns 
white a4 er a meal because of the absorp-
tion of dietary fats as  rst described by 
Asellio during the Renaissance. * e tradi-
tional functions of the lymphatic system 
are ascribed to circulatory physiology and 
immunology. Fluid leaking through the 
semipermeable capillary bed into the 
interstitium, a4 er picking up antigens and 
immunologically active cells, is collected 
in lymph capillaries, drained to regional 
lymph nodes, and exposed to the lymphoid 
system. A4 er  ltration, the lymph 9 uid 
returns to the blood and continues its life-
long task: the draining of organs under 
physiological conditions. * e lymph drain-
age system becomes especially challenged 
during disease conditions such as wound 
healing, inflammation, and infection, 
when excessive 9 uid, lymphocytes, and 
dendritic cells travel through the lymphatic 
vessels to the lymph nodes. * is is not an 
indolent process, but a masterminded sys-
tem in which adhesion molecules, 
cytokines, and chemokines are crucially 
involved. During disease states, the 
number and maturation state of dendritic 
cells increase dramatically. Knowledge of 
how leukocytes migrate over the lymphatic 
wall is sparse, although intercellular adhe-
sion molecule-1 (ICAM-1) and vascular 
cell adhesion molecule-1 (VCAM-1) are 
known to be involved, as ICAM-1-de -
cient mice have a defect in lymph node 
recruitment of dendritic cells. * e role of 
cellular traI  cking through the lymphatic 
system also painfully reveals unappreci-
ated side e: ects such as are seen in the 
dissemination of metastatic cancer cells. 
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